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ABSTRACT
Defining the mutational landscape of classic Hodgkin lymphoma is still a major 
research goal. New targeted next-generation sequencing (NGS) techniques may 
identify pathogenic mechanisms and new therapeutic opportunities related to this 
disease. We describe the mutational profile of a series of 57 cHL cases, enriched in 
Hodgkin and Reed-Sternberg (HRS) cells.
Overall, the results confirm the presence of strong genomic heterogeneity. 
However, several variants were consistently detected in genes related to relevant 
signaling pathways, such as GM-CSF/IL-3, CBP/EP300, JAK/STAT, NF-kappaB, and 
numerous variants of genes affecting the B-cell receptor (BCR) pathway, such as 
BTK, CARD11, BCL10, among others. This unexpectedly high prevalence of mutations 
affecting the BCR pathway suggests some requirement for active BCR signaling for cHL 
cell viability. Additionally, incubation of a panel of cHL cellular models with selective 
BTK inhibitors in vitro constrains cell proliferation and causes cell death. Our results 
indicate new pathogenic mechanisms and therapeutic opportunities in this disease.
INTRODUCTION
Classic Hodgkin lymphoma (cHL) consists of a 
clonal proliferation of the distinctive Hodgkin and Reed 
Sternberg (HRS) cells, diluted in a reactive inflammatory 
microenvironment [1]. HRS cells have customarily 
been characterized by a defective B cell expression 
program [2], probably as a result of the downregulated 
expression of numerous B cell transcription factors [3], 
and epigenetic mechanisms [4]. Thus, although HRS 
cells are derived from mature B cells, they have largely 
lost the B cell phenotype and are unable to express 
immunoglobulins / B-cell receptor (BCR) and other B 
cell surface markers.
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Few studies have attempted to identify gene 
mutations in cHL, and only mutations in specific members 
of the NF-kappaB and JAK/STAT pathways have been 
consistently identified [5–8]. A major limitation of 
gene sequencing of cHL is the scarcity of tumoral HRS 
cells, which account for fewer than 1-2% of all cells, as 
identified by standard CD30 immunostaining.
The advances in next-generation sequencing 
(NGS) technologies have allowed rapid genome-wide 
characterization of single-nucleotide variants (SNVs) 
and indels in cancer, and the genetic landscapes of 
many solid tumors and hematological malignancies 
have been demonstrated [9–12]. The first whole exome 
sequencing analyses of primary HRS cells have recently 
been described, in which beta-2-microglobulin (B2M) 
was identified as the most commonly altered gene [12]. 
However, this study focused on the detection of highly 
prevalent mutations, and had obvious limitations for the 
detection of subclonal variants due to the shallow depth of 
sequencing inherent in full exome analysis technologies.
In recent years, the sensitivity and specificity 
of NGS techniques have been greatly improved by 
simultaneously testing selected genes, arranged in specific 
comprehensive gene panels. This approach is also useful 
when sample material is limited, and even for formalin-
fixed paraffin-embedded (FFPE) tissue samples. We 
hypothesized that combining sequencing techniques 
with increased coverage, and more sensitive and specific 
bioinformatic algorithms, could also allow identification 
of pathogenic SNVs that are present at low frequencies in 
this disease.
Here we analyze the genomic heterogeneity of a 
large series of 57 cHL cases. We used a semiconductor-
based (Ion Torrent) sequencing platform with a custom-
designed gene panel coupled with HRS cell-enrichment 
procedures to establish the mutational landscape of this 
tumor in greater detail. Several variants were consistently 
identified in genes related to relevant signaling pathways, 
such as GM-CSF/IL-3, JAK/STAT, NF-kappaB, and 
also many variants of genes affecting the BCR pathway, 
such as BTK, CARD11, BCL10, and others. Moreover, 
selective-BTK inhibitors were found to constrain 
cell proliferation and cause cell death in cHL cellular 
models with comparable efficiencies to other cell B-cell 
lymphoma models.
RESULTS
Recurrent mutations in cHL
Clinical characteristics of the patients are described 
in Table 1. It is of particular note that 34% of cases in this 
series had primary refractory cHL, and 28.3% of tumors 
were EBV-positive.
Using the described NGS targeted protocol, the 
number of candidate somatic SNVs detected per case was 
found to range from 27 to 587. Cases with low numbers 
of SNVs detected in each duplicate had high concordance 
ratios (Supplementary Figure 1), whereas cases with high 
numbers of SNVs showed low concordance, which means 
that there is either very extensive clonal diversity (many 
mutations with very low variant allele frequencies) or that 
some SNVs actually represent sequencing errors in cases 
with poorer DNA preservation. This observation confirms 
the presence of strong genomic heterogeneity, and 
reinforces the relevance of filtering SNVs using duplicate 
analyses in this study.
Figure 1 and Supplementary Table 4 summarize 
the details of the SNVs. After filtering, we found 63 
concordant SNVs in 57 samples. The mean read depth of 
the targeted regions was 740.32. Non-synonymous SNVs 
were identified in 23 out of the 57 cases (40.35%). We 
found a high percentage of C>T changes (nearly 46%), 
probably due to the dipyrimidine context (Supplementary 
Table 4) [13]. As other authors have noted [8], some of the 
cases had more than one SNV per gene, as in the cases of 
EP300, BTK, CSF1R and CD19.
We found the predicted damaging effect of the SNVs 
in 24 out of the 36 genes analyzed (66.6%). Of these, 
4 genes had mutation rates greater than 10%: CSF2RB, 
EP300, STAT6, and BTK (Figure 1 and Supplementary 
Figure 2). This finding may reflect the importance of 
the deregulation of relevant signaling pathways (such as 
JAK/STAT and BTK), and the relevance of epigenetic 
deregulation.
Some of the variants were also identified in cHL-
derived cell lines, and validated using Sanger sequencing. 
They affected genes such as CARD11, STAT6, CSF2RB, 
B2M, and NFKBIA (Figure 2 and Supplementary Table 5). 
Consistent with our results, some of these SNVs, such as 
those of STAT6, B2M, and NFKBIA, have been described 
as mutations in previous NGS analyses of cHL cell lines 
[14].
Functional studies
Unexpectedly, we identified a large number of 
mutations affecting the BTK gene (10.3% of cases) and 
other members of the BCR pathway (such as CARD11, 
BCL10, and NFKBIA, which were present in up to 21% 
of cases), suggesting that there are some dependencies 
of active BCR signaling despite the known absence of 
BCR expression in HRS cells. To evaluate BCR signaling 
activation in cHL, 6 cHL cell lines, the HBL1 ABC-type 
DLBCL cell line, the DOHH2 GC-type DLBCL cell 
line, and the control HEK293T and HeLa cell lines were 
interrogated. The NFkappaB subunit p52 was strongly 
expressed in all the cHLs analyzed and both DLBCL cell 
lines, providing further evidence of the well-known role 
of NFkappaB in lymphocyte survival (Figure 3A). Since 
NFkappaB activation may be the result of activation of 
several survival pathways, we analyzed the expression of 
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other proteins involved in BCR signaling. BTK protein 
expression was found in all cHL cell lines at similar levels, 
unlike BTK Tyr223 phosphorylation, which was only 
found in DLBCL cells (HBL1 and DOHH2) and some of 
the cHL cell lines (L428 and HDML2) (Figure 3A). In 
addition to BTK expression, activation of NFkappaB via 
BCR signaling was explored by CYLD cleavage, a direct 
downstream target protein of the BCR pathway. CYLD 
cleavage by western blot was observed in all cHL cell 
lines and DLBCL cell lines at similar levels, supporting 
the hypothesis that there is some level of basal activation 
of the BCR cascade in cHL.
We therefore examined the activity of selective 
BTK inhibitors in cHL cell lines. First, we used ibrutinib, 
a specific BTK inhibitor approved for therapy for various 
B cell-derived malignancies. Ibrutinib toxicity curves 
showed a similar IC50 range of 10-50 μM in both models: 
DLBCL (HBL1) and cHL cell lines, without significant 
differences (Figure 3B). To confirm these findings we 
incubated the cells with a second experimental BTK 
inhibitor (AVL-292), which yielded similar IC50 ranges 
in all the cell lines analyzed. Indeed, the IC50 after BTK 
inhibition with ibrutinib was similar in other cell models 
of B-cell malignancy, such as mantle cell lymphoma (data 
not shown).
Consistent with this, IHC staining of the tumor 
samples using TMAs showed common BTK protein 
expression in the neoplastic HRS cells (72% of cases), 
with unusually strong expression in 8% of cases (Figure 
4). We also found a significant correlation between FFS 
and the presence of BTK gene mutations (Figure 4C) and a 
just-insignificant correlation with BTK protein expression 
(Figure 4D).
DISCUSSION
Although cHL is generally a highly curable disease, 
a significant fraction of patients nevertheless have 
relapsing disease and eventually die due to treatment 
resistance or late treatment-associated toxicities [15]. 
Table 1: Clinical characteristics of patients
FEATURE N %
Age (years)
 < 45 37 68.52
 ≥ 45 17 31.48
Gender
 Male 26 48.15
 Female 28 51.85
IPS
 0-2 35 64.81
 ≥ 3 19 35.19
Outcome
 Refractory 18 33.96
Complete response 35 66.04
Ann Arbor Stage
 < IV 36 67.92
 ≥ IV 17 32.08
Histology
 Nodular sclerosis 34 59.64
 Mixed cellularity 13 22.8
 Lymphocyte-rich 6 10.53
  NA 4 7.03
EBV
 Positive 15 28.3
 Negative 38 71.7
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Thus, the identification of new therapeutic alternatives 
and the better biological characterization of the subgroup 
of patients with refractory disease remain major research 
goals. Here we describe the mutational profile of cHL 
using data initially generated in the initial discovery cohort 
and extend these observations to a large series of 57 cHLs 
using targeted deep sequencing with a restricted list of 36 
genes and duplicate experiments.
We detected recurrent mutations in 24 genes. Other 
authors have reported some of the genes commonly 
mutated in cHL, such as NFKBIA [16] and FAS [17]. It 
is of note that many of the variants identified here have 
also been detected in the recent NGS analysis of primary 
HRS cells [12], including ABL1, B2M, CARD11, CSF2RB, 
MYB, NFKB2, NFKBIA, and STAT6, among others. 
Differences in isolation techniques, sequencing methods, 
filtering criteria, and limitations due to small sample 
sizes may be responsible for some of the discrepancies 
in frequencies. We also identified some previously 
unreported SNVs in BTK and EP300.
We identified several SNVs in genes that had 
previously been described in NGS studies of DLBCL. We 
consistently found variants affecting CARD11, STAT6, 
CREBBP, and CMYB, as described in ABC-type DLBCL 
[9, 11], and STAT6, as known in primary mediastinal large 
B-cell lymphoma [10]. These findings are consistent with 
the well-known molecular similarities between cHL and 
these lymphoma types [10, 18].
Figure 1: Mutational landscape. The diagram shows the distribution of gene variants. 40.3% of samples have at least 1 SNV after 
filtering. We identified variants in 66.6% of the selected genes. One SNV is indicated in red, while genes with more than two SNVs are 
indicated in dark red. The final two columns indicate the number and percentage of mutated genes per case. The bottom two rows indicate 
the number and percentage of cases with at least one SNV.
Figure 2: Mutational landscape in 6 cHL-derived cell lines and Sanger sequencing validation. (A) The diagram shows 
the distribution of mutations per cell line. One SNV is indicated in red, while two SNVs per gene are indicated in dark red. Black boxes 
correspond to SNVs validated by Sanger sequencing. (B) Representative example, CARD11 mutation in the KMH2 cell line; IGV diagram 
(Ion Torrent sequencing) and Sanger sequencing representation.
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Figure 3: Functional studies in cHL-derived and DLBCL-derived cell lines. (A) Western blot analysis of total BTK, CYLD 
truncation, NFKB (p52 isoform), and phospho-IkBα. (B and C) Activity of BTK selective inhibitors in cHL-derived and DLBCL-derived 
cell lines. IC50 range calculation of HBL1, HDLM2, L540, and L1236 cell lines in the presence of different concentrations of Ibrutinib or 
AVL-292, after 48 hours.
Figure 4: Btk IHC expression in HRS cells and Its correlation with survival. (A) Representative examples of IHC for Btk 
expression in cHL tissues. (B) Distribution of Btk protein expression in our series. Positivity (+) was concluded for cases with a level of 
expression comparable to that seen in normal germinal center B lymphocytes. (C) Kaplan–Meier survival curves demonstrate longer FFS 
in wt-BTK cases (P<0.05). (D) Survival curves demonstrate a longer FFS in cases with a low level of expression of Btk protein (P=n.s.).
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The most frequent genetic lesions potentially 
affect relevant signaling pathways in B cell biology (see 
Supplementary Materials): JAK/STAT, NF-kappaB, and 
numerous variants of genes affecting the B cell receptor 
(BCR) pathway, such as BTK, CARD11, and BCL10, 
among others. Epigenetic regulation also seems to be a 
common target for mutational events (EP300, CREBBP).
EP300 encodes an adenovirus E1A-associated 
cellular p300 transcriptional coactivator protein and 
functions as a histone acetyltransferase and regulates 
transcription via chromatin remodeling. Histone acetylation 
gives an epigenetic tag for transcriptional activation. It 
mediates cAMP-gene regulation by binding specifically 
to phosphorylated CREB protein. It also functions as an 
acetyltransferase for non-histone targets. Mutations in the 
histone acetylation domain of EP300 are present in 14% of 
the samples, similar to what is seen in DLBCL and follicular 
lymphoma [19, 20]. Interestingly, the inhibition of the CBP/
p300 bromodomain has been recently introduced as a 
promising therapy for lymphoproliferative disorders [21].
CSF2RB (colony stimulating factor 2 receptor beta 
common subunit) encodes the common beta chain of the 
high-affinity receptor for interleukin-3, interleukin-5, and 
granulocyte-macrophage colony-stimulating factor. Its 
function is critical for the activation of the JAK/STAT and 
MAP kinase pathways. In this series, we found low allele 
frequency SNVs in 7 samples (12.3%). One particular 
SNV, V212I, is recurrent in 4 of the cHL cases. This 
alteration is located in the fibronectin type III domain 
(FIB). The RGD sequence (Arginine-Glycine-Aspartic 
acid), which is involved in the interaction with integrin, 
is located in this domain, and modulates a variety of cell 
adhesion events associated with thrombosis, inflammation 
and tumor metastasis [22].
STAT6 (Signal Transducer and Activator of 
Transcription 6, Interleukin-4 Induced) encodes a member 
of the STAT family of transcription factors, plays a central 
role in exerting IL4-mediated biological responses, and 
induces the expression of BCL2L1/BCL-X(L), which 
is responsible for the anti-apoptotic activity of IL4. We 
found 7 SNVs in 7 cases (12.3% of samples), most of 
which are located in the DNA binding domain, as has been 
found in previous studies of primary mediastinal DLBCL. 
Functional studies in cell lines have shown that mutations 
in this domain reduced DNA-binding ability [10].
BTK is a non-receptor tyrosine kinase that 
is indispensable for B lymphocyte development, 
differentiation, and signaling. Binding of antigens to 
the BCR triggers signaling that ultimately leads to 
B-cell activation. This gene has been implicated in the 
pathogenesis of chronic lymphocytic leukemia, mantle 
cell lymphoma, DLBCL and other B-cell malignancies. 
We have seen 7 different SNVs in 6 samples (10.3% of 
our series). Ibrutinib is an irreversible inhibitor of BTK, 
binding to cysteine 481 in the protein tyrosine kinase 
domain (ATP binding site). Woyach et al [23] have 
recently identified a cysteine-to-serine mutation at the 
ibrutinib binding site in treated patients that results in 
a protein that is only reversibly inhibited, and could be 
associated with therapy resistance. This specific alteration 
is different from all the SNVs that we found in our series, 
located at different functional domains, mainly affecting 
the PH domain, which is involved in establishing the 
location of the protein and its membrane anchoring. 
The BTK subcellular localization in tumor cells is a 
key process for the activation of the pathway and BTK 
mutations affecting this functional domain may also be 
related with BCR signaling activation [24].
Unexpectedly, we observed numerous variants of 
genes affecting the BCR pathway, such as BTK, CARD11, 
and BCL10. These findings suggest that there may be a 
requirement for active BCR signaling to ensure cHL cell 
viability, even though BCR is not expressed by HRS cells. 
Consistent with this interpretation, we found evidence 
of the basal activation of the pathway in cHL cell lines, 
and that the incubation of a panel of in vitro cell models 
with specific BTK inhibitors constrains cell proliferation 
and causes cell death. However, from our results we 
must also recognize the potential overlap between BCR 
signaling and the canonical NF-kappaB pathway, making 
it difficult to establish firm conclusions. In addition, some 
BTK-independent effect of the inhibitors in different cell 
models cannot be ruled out. Previous studies reported 
BTK expression in only approximately 20% of patients 
with cHL [25], but here we detected very frequent BTK 
protein expression in cHL tumors, as well as some 
correlation between protein expression, BTK gene mutation 
and survival. In accordance with our observations, the 
clinical value of ibrutinib in cHL patients was partially 
demonstrated in a recent communication by Hamadani 
et al [26], who administered ibrutinib as a single agent to 
two heavily pretreated patients with primary refractory 
cHL. One of the patients showed near-complete regression 
of disease two months after the initiation of therapy that 
lasted for 4 months. The second patient showed a stable 
complete response 4 months after the initiation of ibrutinib.
In conclusion, our results confirm the presence of 
strong genomic heterogeneity in cHL. However, it appears 
that recurrent targets are subject to functional mutations 
and suggest the existence of some tumor dependencies 
that could be exploited for therapeutic purposes. The 
activity of selective BTK inhibitors in patients with 
refractory cHL, as well as the inhibition of the CBP/
p300 bromodomain and JAK/STAT pathways, need to be 
evaluated in prospective clinical studies.
MATERIALS AND METHODS
Patient samples
Pretreatment FFPE tumor samples and clinical data 
from 57 cHL patients were obtained from the files of 
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participant institutions. cHL was confirmed histologically 
in all cases by central review.
Samples were collected in accordance with the 
technical and ethical procedures of the Spanish National 
Biobank Network, including anonymization processes 
and written informed consent, according to the Helsinki 
Declaration. Approval was obtained from the institutional 
review board (Clinical Research Ethical Committee, ref. 
354/12).
Gene selection and Ampliseq design
Target genes were selected by analyzing the 
mutational profile of cHL with Illumina GAII and Sure 
Select technology (Agilent Technologies, Santa Clara, 
CA, USA) in an initial discovery cohort of 7 tumor tissue 
samples (freshly frozen) from 4 cHL cases, with a targeted 
analysis of 522 genes involved in lymphomagenesis 
and B and T cell-related pathways (Supplementary 
Table 1). Sequences were analyzed with the RAMSES 
(Realignment-Assisted Minimum Evidence Spotter) 
algorithm [27], which has been specifically designed to 
detect low-frequency variants for the Illumina platform. 
This software uses minimum high confidence evidence, 
based on the use of multiple short read aligners, of the 
presence of sequence variants at a specific position. 
Considering the great extent of coverage obtained in this 
project, we established a minimum of 20 high-confidence 
reads reporting a different base in a specific mutation to 
conclude the presence of a mutation. We also filtered out 
all the variants reported in dbSNP and the 1000 Genomes 
project as probable germline variants. Small insertions and 
deletions (indels) were identified using PINDEL [28].
Two predictive algorithms (PROVEAN [29] and 
Alamut [13]) indicated that 54 variants of 48 genes had a 
deleterious effect on protein function. From these results, 
we selected 25 genes filtered by established criteria based 
on sequencing quality and discovery cohort population 
frequency (consistently mutated in at least two samples). 
As additional controls, we added 6 genes (detected in 
single samples) to this design with previously reported 
mutations in diffuse large B-cell lymphomas (DLBCLs) 
or in cHL, as well as 4 genes of biological relevance in 
this type of lymphoma (Supplementary Table 2). These 
35 coding regions from target genes were included in an 
Ampliseq Custom Panel for sequencing using the Ion 
Torrent platform.
Sequencing techniques
To isolate DNA, tumor samples were enriched in 
HRS cells by selecting the most representative regions 
(those containing more than 10% of tumor cells), using 
a 1-mm-diameter puncher (Quick-Ray Tissue Microarray 
System, IHC World, Woodstock, MD, USA) from tumor 
issues of at least 1-mm thickness.
DNA was extracted from FFPE tissue and from 
cell lines using standard procedures. Ion Torrent adapter-
ligated libraries were constructed using an Ampliseq 
Custom Panel (Thermo Fisher Scientific, NY, USA), 
including the 35 selected genes distributed in 353 
amplicons, starting with 10 ng of genome DNA and 
following the manufacturer´s protocol.
Sample emulsion PCRs and enrichment were 
performed using Ion PGM Template OT2 200 Kit (Thermo 
Fisher Scientific), and the libraries were sequenced using 
318 v2 chips with Ion PGM Sequencing 200 v2 (Thermo 
Fisher Scientific). To minimize false-positive rates, all 
sequencing procedures were done in duplicate (parallel 
libraries constructed from two independent PCRs from 
separate aliquots of isolated genomic DNA). For filtering 
polymorphisms and germinal variants we included the 
available germline DNA from 5 cases in order to generate 
control pool DNA.
Variant calling and screening for somatic 
mutations
The sequencing data were analyzed with the Torrent 
Suite program with the “variant caller” plug-in program, 
selecting somatic low stringency mode to detect SNVs 
with low allele frequency. We restricted the analyses 
to variants with a total coverage of at least 100x, and a 
minimum variant coverage of 10x. In addition to filtering 
with the control pool of germline DNAs, we also filtered 
variants with an allele frequency >40%, to minimize the 
detection of germline variants. To eliminate erroneous 
base calling, all variants were examined with Integrative 
Genomics Viewer (IGV) software [30], comparing 
each duplicated sample and discarding non-concordant 
variants. In addition, to evaluate the reproducibility of this 
approach, we calculated the concordance ratios between 
duplicates (Supplementary Figure 1) [31]. Finally, 
functional consequences of the SNVs were predicted using 
the PROVEAN and Alamut algorithms, filtering variants 
with no damaging effect in the prediction [13, 29].
We also analyzed six cHL-derived cell lines 
(L428, L1236, HDLM2, L540, KMH2, and L591), using 
the same sequencing procedure and filtering criteria, 
and by conventional Sanger sequencing to validate 
high allele frequency mutations (Supplementary Table 
3). Cell lines were newly obtained from the German 
Collection of Microorganisms and Cell Cultures 
(DSMZ, Braunschweigh, Germany). All cell lines were 
authenticated by DMSZ using DNA profiling
Cell culture, drug treatment, protein extraction, 
and western blot analyses
For in vitro studies we included the six cHL cell 
lines and DLBCL cell lines (HBL1 and DOHH2) (DSMZ).
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For functional experiments, we purchased 
ibrutinib (Selleckchem, Houston, TX) and AVL-292 
(MedchemExpress, Monmouth Junction, NJ) selective 
BTK (Bruton tyrosine kinase) inhibitors. To calculate the 
half-maximal inhibitory concentration (IC50), 20,000 cells 
were incubated with various concentrations of ibrutinib or 
AVL-292 for 48 hours. Viable cells were quantified by the 
AlamarBlue protocol (Fisher Scientific, Waltham, MA), 
following the manufacturer’s instructions. Experiments were 
performed in duplicate and repeated at least three times.
Apoptosis was estimated after 8 hours of treatment 
at 37°C, by analyzing PARP cleavage by western blot. 
Additional western blot analyses were done using 
monoclonal antibodies against CYLD N-terminal 
(ab153698) (ABCAM, Cambridge, UK), Phospho-BTK 
(Tyr223), Phospho-IκBα (Ser32) (14D4) (Cell Signaling, 
Danvers, MA), BTK (7F12H4) (Santa Cruz Biotechnology, 
Santa Cruz, CA), NFκB p52 (MERCK, Madrid, Spain) and 
α-tubulin (Sigma Aldrich, St. Louis, MO).
Immunohistochemistry (IHC)
Representative tumor areas from FFPE tumor 
samples were included in duplicate in a tissue microarray 
(TMA). IHC analysis was performed using heat-induced 
epitope retrieval and standard procedures, using anti-
Btk monoclonal antibody (7F12H4, Santa Cruz). Protein 
expression was quantified using an automated scan, 
Chroma Vision Systems-ACIS III (DAKO, Glostrup, 
Denmark), as previously described [32].
Statistical analyses
Correlations between variables and overall survival 
(OS) and failure-free survival (FFS) were estimated by 
the Kaplan–Meier method and the curves were compared 
using the log-rank test. Differences were considered 
statistically significant for values of P<0.05. All statistical 
analyses were performed using SPSS version 17.0 (SPSS 
Inc., Chicago, IL).
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